Surveillance Solutions for Detection, Discrimination, and Discovery of Emerging SARS-CoV-2 Variants
Jelena Feenstra, PhD
Senior Manager, Global Scientific Communications
Thermo Fisher Scientific
The emergence of novel SARS-CoV-2 variants can have profound effects on efforts to fight the ongoing COVID-19 pandemic. According to the US CDC, several Variants of Concern (VOC) / Interest (VOI) are circulating in the U.S., including B.1.1.7 (UK variant), B.1.351 (SA variant), P.1 (Brazilian variant), B.1.526 (NY variant), B.1.427/B.1.429 (California variant). Besides being more transmissible or, potentially more lethal, these VOC may lead to therapy resistance, reduced effectiveness of COVID-19 vaccines or impact performance of diagnostic assays. It is, therefore, of utmost importance to perform genomic surveillance for SARS-CoV-2. In this webinar, we will discuss the different options for the detection, discrimination and discovery of emerging SARS-CoV-2 variants. This may allow public health laboratories to implement different strategies and efficiently utilize their testing resources while scaling up surveillance testing as the world moves from a pandemic to an endemic environment.
Please fill out the form to access this webinar.
Intended use and regulatory statements of products vary. For specific intended use and regulatory statements please refer to the Instructions for Use (IFU). Product availability by country varies.